FDA approves Lumicell’s breast cancer imaging tool
April 22, 2024
Lumicell developed the technology to help physicians detect residual cancer in the breast cavity after surgery.
Lumicell developed the technology to help physicians detect residual cancer in the breast cavity after surgery.
The Osia System, which launched commercially in 2020, is indicated for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD)
Lumicell today announced it received FDA approval for its LumiSystem direct visualization system for breast cancer removal.
The company’s 3rd FDA clearance accelerates the shift to AI-powered digital hematopathology, enhancing diagnostic speed and patient care
IRVING, Texas, April 16, 2024 /PRNewswire/ — Xstim, Inc., a pioneering developer and manufacturer of cutting-edge bone growth stimulation systems, is thrilled to announce its recent Premarket Application (PMA) approval from the U.S. Food and Drug Administration (FDA) for Xstim™ Spine Fusion Stimulator
The 3D printed PEEK implants using the EXT 220 MED were successfully demonstrated in nearly 40 cranioplasties across Europe in recent months says the company.
Simpson Interventions announced this week that it received FDA breakthrough designation for its Acolyte image-guided crossing and re-entry catheter system.
The Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for the early detection of fetal distress during labor and delivery.
Onkos Surgical this week announced it received FDA de novo approval for its antibacterial coated implants.
Vivos Therapeutics specializes in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults).